“Te BCRP’s strategic approach is to invest in research that addresses the over- arching challenges in breast cancer and will lead to breakthroughs toward ending this disease,” said Dr. Gayle Vaday, pro- gram manager. Tere is no denying how far breast cancer research has come in the last quarter-century. What once was seen as a dire diagnosis has become one of the most treatable cancers, thanks to success- ful research.
“Over the years, the BCRP funding has been instrumental in supporting timely, state-of-the-art research that has led to clinical approaches used for patients today, including targeted therapies, like trastuzumab; imaging, such as digital mammography and breast tomosyn- thesis; and genetic risk assessments like OncoVue and the Breast Cancer Index,” Vaday said. Te BCRP has also supported more recent trends in cancer immunotherapies and vaccines, as well as cell-cycle inhibitors, and continues to encourage innovative research ideas, she said.
INCORPORATING MANY PERSPECTIVES Since the Breast Cancer Research Pro- gram marked the beginning of the CDMRP, research programs have been modified each year as directed by Con- gress; the CDMRP is responsible for determining the appropriate strategy and managing the selection process. Cur- rently there are 31 research programs supporting dozens of topics in areas such as cancer, neurological disorders, trau- matic injuries and rehabilitative medicine.
Te Institute of Medicine (now called the National Academy of Medicine) provided guidance suggesting a two- tier review process. CDMRP adopted this process, which includes both peer and programmatic reviews to guide the
funding recommendations. (See ure 1.) Te
two-tier process
Fig- includes
participation by consumer advocates who have experienced the program-spe- cific illness, disease or disorder in both reviews, as well as in the development of investment strategies and research focus areas. Tis has become a hallmark of the CDMRP: developing a unique col- laboration in the scientific review process among public and private stakeholders including the military, scientists, clini- cians, policymakers, disease
survivors,
patients, family members and caregivers, providing many different facets of exper- tise when reviewing research.
Maxwell Ramsey, a consumer reviewer on the Peer Reviewed Orthopedic Research Program (PRORP), learned of the CDMRP through a forwarded email chain from an outreach worker at the Walter Reed National Military Medical Center. “My journey of recovery was not unlike many other amputees at Walter Reed,” said Ramsey, who was wounded in action on March 1, 2006. “I made it a point to excel in my recovery so I was [as] highly functional as possible. I remained in the Army for a couple of years after get- ting out of the hospital—jumping out of planes for the 101st Airborne Division’s Parachute Demonstration Team—before retiring from the Army in 2009.”
Ramsey had high marks for his experience as a consumer reviewer with the PRORP.
“It was excellent. Te team is very well- organized, and that makes the process, from initial review to feedback to panel discussion, very smooth,” he said. “Person- ally, I thrive in environments surrounded by hyper-intelligent academics and find the ideas we discuss to be very exciting.”
Consumers like Ramsey serve as voting members on nearly all CDMRP peer and programmatic review panels. Invitations
ON THE MARCH
The National Breast Cancer Coalition in 1992 sought an increase in federal appropriations for breast cancer research. Its grass-roots campaign of letter writing, petition signing, lobbying and marching led to $210 million in additional funding and the eventual formation of CDMRP. (Photo courtesy of the National Breast Cancer Coalition)
“We did letter writing, petition signing, and held lobby days on Capitol Hill, where we brought in women to meet with their senators and representatives. We stood outside committee rooms and on the steps of the Capitol.”
HTTPS: / /
ASC.ARMY.MIL
101
SCIENCE & TECHNOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168
